|
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. |
|
|
Employment - AstraZeneca (I) |
Consulting or Advisory Role - Abbvie; AMGEN; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Ipsen; Janssen; LEO Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Takeda |
Research Funding - AstraZeneca (Inst); BMS (Inst); MSDavenir (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology; Janssen Oncology; Roche |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda |
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda |
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Speakers' Bureau - ABL Bio; Ono Pharmaceutical; Roche/Genentech |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda |
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis |
Research Funding - MSD Oncology (Inst) |
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical |
Consulting or Advisory Role - Janssen |
Research Funding - Bayer; Gilead Sciences; Janssen; Japan Clinical Research Operations; Merck; Ono Pharmaceutical; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer |
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer Pharma Japan. (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Eisai (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly Japan (Inst); Merck (Inst); Merus (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer |
|
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Janssen; Kyowa Kirin; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda |
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics |
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Peervoice; Pfizer; Roche; Sanofi; Takeda; Touch Oncology |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche |
Other Relationship - GRIFOLS |
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023 |
|
|
Consulting or Advisory Role - AstraZeneca; Takeda |
Travel, Accommodations, Expenses - MERCK |
|
|
Consulting or Advisory Role - MSD Oncology (Inst) |
Travel, Accommodations, Expenses - MSD (Inst) |
|
|
Honoraria - Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst) |
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); DKSH (Inst); Genmab; Merck (Inst); Pfizer (Inst); Roche (Inst); Zymeworks |
Research Funding - ACM Biolabs (Inst); AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche |
|
|
Stock and Other Ownership Interests - BlossomHill Therapeutics |
Consulting or Advisory Role - Abbvie; ABION; ArriVent Biopharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Novartis; Regeneron; Sensei Biotherapeutics; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical |
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst) |
Travel, Accommodations, Expenses - EMD Serono; Spectrum Pharmaceuticals |
|
|
Employment - Employment at Bayer Consumer Care AG, Basel, Switzerland |
|
|
Employment - Employment at Bayer S.p.A. |
|
|
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific |
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health |
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst) |